---
title: "Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291926978.md"
description: "Recently, a hot line presentation revealed primary results from ACACIA-HCM study, focusing on patients with non-obstructive hypertrophic cardiomyopathy. The presentation aimed at elaborating on the favorable topline results. Key statistics from the study were shared, showcasing the positive outcomes in this specific patient population. This presentation provided further insights into the effectiveness of the treatment in improving the condition of individuals with non-obstructive hypertrophic cardiomyopathy."
datetime: "2026-07-07T11:31:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291926978.md)
  - [en](https://longbridge.com/en/news/291926978.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291926978.md)
generator: "portal-rs"
---

# Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Recently, a hot line presentation revealed primary results from ACACIA-HCM study, focusing on patients with non-obstructive hypertrophic cardiomyopathy. The presentation aimed at elaborating on the favorable topline results. Key statistics from the study were shared, showcasing the positive outcomes in this specific patient population. This presentation provided further insights into the effectiveness of the treatment in improving the condition of individuals with non-obstructive hypertrophic cardiomyopathy.

### Related Stocks

- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)

## Related News & Research

- [Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCM - Has The Bull Case Changed?](https://longbridge.com/en/news/297408476.md)
- [Cytokinetics Investors Weigh Safety Data From Pivotal Trial](https://longbridge.com/en/news/297549493.md)
- [Alnylam announces new data at ESC Congress on AMVUTTRA](https://longbridge.com/en/news/297453980.md)
- [Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026](https://longbridge.com/en/news/297300803.md)
- [Cytokinetics posts MAPLE-HCM presentation on aficamten vs metoprolol in obstructive hypertrophic cardiomyopathy](https://longbridge.com/en/news/297405384.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**